{"transactions":[{"id":758921,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T20:21:57.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026."}],"balance_after":80000,"derivative":{"exercise_price":1.86,"expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001610717-26-000170","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000170/form4.xml","form_type":"4"}},{"id":1129416,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:17.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025."}],"balance_after":80000,"derivative":{"exercise_price":0.72,"expiration_date":"2035-05-27","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-25-079918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079918/ownership.xml","form_type":"4"}},{"id":1129415,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:17.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":28571,"derivative":{"exercise_price":0.72,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-079918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079918/ownership.xml","form_type":"4"}},{"id":1129414,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:17.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":46455,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":46455,"derivative":{"exercise_price":0.72,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":46455},"source":{"system":"sec-edgar","filing":"0000950170-25-079918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079918/ownership.xml","form_type":"4"}},{"id":1129413,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:17.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-079918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079918/ownership.xml","form_type":"4"}},{"id":1129412,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:17.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":46455,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":46455},"source":{"system":"sec-edgar","filing":"0000950170-25-079918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079918/ownership.xml","form_type":"4"}},{"id":1264065,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:03.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":28571,"derivative":{"exercise_price":1.69,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-022318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022318/ownership.xml","form_type":"4"}},{"id":1264064,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:03.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":46455,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":46455,"derivative":{"exercise_price":1.69,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":46455},"source":{"system":"sec-edgar","filing":"0000950170-25-022318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022318/ownership.xml","form_type":"4"}},{"id":1264063,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:03.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":0,"derivative":{"exercise_price":9.95,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-022318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022318/ownership.xml","form_type":"4"}},{"id":1264062,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:03.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":46455,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2023-09-14","underlying":"Common Stock","underlying_shares":46455},"source":{"system":"sec-edgar","filing":"0000950170-25-022318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022318/ownership.xml","form_type":"4"}},{"id":1479376,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:14:28.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":28571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":28571,"derivative":{"exercise_price":9.95,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0001610717-24-000336","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000336/form4.xml","form_type":"4"}},{"id":1479375,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-14T20:14:28.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":20100,"source":{"system":"sec-edgar","filing":"0001610717-24-000336","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000336/form4.xml","form_type":"4"}},{"id":1779111,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":43209,"kind":"person","name":"Halawa Alaa","position":1,"cik":"0001992622","reported_name":"Halawa Alaa","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-18T21:52:59.000Z","date":"2023-09-14","kind":"grant","planned":false,"acquired":true,"shares":46455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":46455,"derivative":{"exercise_price":17,"expiration_date":"2033-09-13","underlying":"Common Stock","underlying_shares":46455},"source":{"system":"sec-edgar","filing":"0001610717-23-000283","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071723000283/form4.xml","form_type":"4"}}]}